Background COPD is a chronic respiratory disease that is characterized by an inflammation of the airways which thus limits airflow in the lungs. It ranks amongst the major disorders and diseases that affect human life globally with smoking being the major cause. Management strategies now bear the task of slowing down the progression of the disease as well as decreasing the frequency of exacerbations. Objectives To assess the quality of pharmacologic and non-pharmacologic COPD management strategies in terms of lung function, frequency of exacerbations and patient’s quality of life. Study design : A retrospective cohort study. Methods Data of 200 patients diagnosed with COPD, who attended Tertiary care hospital between 2015 and 2020, were used in this retrospective analysis. Patients were then subdivided according to the severity of disease and treatment. This was achieved through the assessment of outcomes like lung function, frequency of exacerbations and hospitalization. Results This study involved 200 patients of which were 121(60. 5%) males and 79(39. 5%) female the mean age was 65(SD=10). Of the patients, GOLD 3-4 had a higher exacerbation rate of 35% than the patients with GOLD 1-2 of 15% (p = 0. 01). FEV1 increased by 12 percent in patients using both long acting bronchodilators (p = 0. 05). There was a highly statistically significant improvement of symptoms of pulmonary rehabilitation in patients with pulmonary fibrosis with a responder rate of 75% (P= 0. 02). Conclusion COPD treatments and pulmonary rehabilitation decrease the frequency of exacerbations and enhance patients’ quality of life. It is also important to emphasize, that the beginning of treatment plays a great role in achieving positive outcomes especially in the population with moderate to severe AD.